The Effects of Dietary Peptides on Human Brown Fat

The Effects of Dietary Peptides on Human Brown Adipose Tissue

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2016-002373-35-FI

Enrollment

Registered

2016-06-09

Start date

2016-07-04

Completion date

Unknown

Last updated

2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

Trade Name: Secrelux Pharmaceutical Form: Concentrate for solution for injection/infusion INN or Proposed INN: SECRETIN HYDROCHLORIDE CAS Number: 17034-35-4 Concentration unit: U unit(s) Concentration

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Male sex Age 18-65 years BMI 20-26 kg/m2 Fasting plasma glucose less than 6.1 mmol/l Normal oral glucose tolerance test Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 15 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: BMI above 26 or below 20. Low or high blood pressure. Asthma or other obstructive lung disease. Sick sinus syndrome, prolonged QT-interval, or any heart disease. Any chronic disease (eg. inflammatory bowel disease or a history of pancreatitis) or medication (eg. beta-blocker, thyroxine, cortisone, oestrogen, progesterone or anticholinergic medications) that could affect the study outcome or pose a risk to subjects. Mental disorder or poor compliance. Eating disorder or excessive use of alcohol, tobacco smoking or drug use. Past dose of radiation in PET studies. Metal, such as pacemaker or surgical steel, in body. Any other condition that in the opinion of the investigator could create a hazard to the subject’s safety, endanger the study procedures or interfere with the interpretation of study results.

Design outcomes

Primary

Measure	Time frame
Main Objective: The purpose of this study is to investigate the effects of secretin on BAT and other tissues. Our hypothesis is that secretin activates BAT. Therefore we will compare BAT perfusion and glucose uptake during secretin and cold activation with placebo in healthy humans, using PET-CT scanning of cervical, thoracic, abdominal and brain areas. We will also investigate full body energy expenditure with calorimetry during scans in these three different conditions, as well as at baseline.;Secondary Objective: Not applicable.;Primary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable	—

Measure

Time frame

Main Objective: The purpose of this study is to investigate the effects of secretin on BAT and other tissues. Our hypothesis is that secretin activates BAT. Therefore we will compare BAT perfusion and glucose uptake during secretin and cold activation with placebo in healthy humans, using PET-CT scanning of cervical, thoracic, abdominal and brain areas. We will also investigate full body energy expenditure with calorimetry during scans in these three different conditions, as well as at baseline.;Secondary Objective: Not applicable.;Primary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable

—

Secondary

Measure	Time frame
Secondary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable	—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026